CanSino Biologics, Inc. Class A 688185
SSE · China · Health Technology
CNY 102.64+17.11 (+20.00%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As global markets react to geopolitical developments and economic data, Asian equities present a unique landscape of opportunities and challenges. In this environment, identifying undervalued stocks requires a keen understanding of market sentiment and macroeconomic factors that could influence future growth potential.
CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (WGS 2026) which convened from February 3 to 5 in Dubai, UAE under the theme of "Shaping Future Governments." CanSinoBIO stands the sole global vaccine maker invited to the World Government Summit for the second consecutive year.
As global markets navigate a complex landscape marked by economic uncertainties and policy shifts, Asian markets have shown resilience, with notable activity in sectors like technology and consumer goods. In this context, companies that combine strong earnings growth with high insider ownership can offer potential stability and alignment of interests between management and shareholders.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.